Cosmo Pharmaceuticals NV
Company Profile
- Business description- Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33. 
- Contact- Sir John Rogerson’s Quay 
 Riverside II
 Dublin2
 IRL- T: +353 18170370 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Drug Manufacturers - General - Fiscal Year End- 31 December 2025 - Employees- 332 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,121.07 | 79.81 | -0.97% | 
| DAX 40 | 23,958.30 | 160.59 | -0.67% | 
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% | 
| FTSE 100 | 9,717.25 | 42.81 | -0.44% | 
| HKSE | 25,906.65 | 376.04 | -1.43% | 
| NASDAQ | 23,724.96 | 143.81 | 0.61% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,840.20 | 17.86 | 0.26% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |